Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$778.97 +8.33 (+1.08%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$779.90 +0.93 (+0.12%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $763, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • Eli Lilly and Co has a strong market presence with a market capitalization of approximately $723.53 billion, indicating stability and potential for long-term growth.
  • The company reported a significant year-over-year revenue increase of 45.2%, showcasing its ability to grow and adapt in a competitive market.

Cons of Eli Lilly and Company

  • The company recently missed earnings expectations, reporting $3.34 EPS compared to the consensus estimate of $4.64, which may raise concerns about its short-term performance.
  • Analysts have issued mixed ratings, with some downgrading their outlook, indicating uncertainty in the stock's future trajectory.
  • The stock has a high price-to-earnings ratio of 62.12, which may suggest that it is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$730.36 billion
P/E Ratio
63.38
Consensus Rating
Moderate Buy
Consensus Price Target
$1,011.61 (+29.9% Upside)
Volume
2.79 million shares
Average Volume
3.65 million shares
Today's Range
$763.02
$784.44
50-Day Range
$713.99
$899.78
52-Week Range
$677.09
$972.53
Dividend Yield
0.78%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$152.27 +0.95 (+0.63%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$152.50 +0.23 (+0.15%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $149.81, which may present a buying opportunity for investors looking for value.
  • Johnson & Johnson recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $2.77, indicating robust financial health.
  • The company has a solid market capitalization of approximately $360.44 billion, reflecting its stability and established presence in the healthcare sector.

Cons of Johnson & Johnson

  • Recent downgrades from analysts, including a reduction in rating from "outperform" to "market perform," may indicate a lack of confidence in short-term growth.
  • The stock has experienced a decline of about 0.6% recently, which could signal potential volatility or market concerns.
  • Johnson & Johnson's price-to-earnings (P/E) ratio of 16.66, while reasonable, may suggest that the stock is not undervalued compared to its peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$364.09 billion
P/E Ratio
16.94
Consensus Rating
Moderate Buy
Consensus Price Target
$170.88 (+12.2% Upside)
Volume
9.54 million shares
Average Volume
7.97 million shares
Today's Range
$150.98
$152.72
50-Day Range
$146.39
$157.68
52-Week Range
$140.68
$169.99
Dividend Yield
3.44%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$185.53 +1.77 (+0.96%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$186.16 +0.63 (+0.34%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $185, which may present a buying opportunity for investors looking for value.
  • AbbVie has shown strong revenue performance, reporting $13.34 billion for the latest quarter, exceeding expectations, which indicates robust business operations.
  • Institutional ownership is high, with over 70% of shares held by institutional investors, suggesting confidence in AbbVie’s long-term prospects.

Cons of AbbVie

  • The price-to-earnings ratio is relatively high at 78.79, which may indicate that the stock is overvalued compared to its earnings.
  • AbbVie has a significant debt-to-equity ratio of 44.14, suggesting that the company relies heavily on debt financing, which can be risky in volatile markets.
  • Despite strong revenue, the net margin is only 7.31%, indicating that profitability may be a concern for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$324.59 billion
P/E Ratio
78.95
Consensus Rating
Moderate Buy
Consensus Price Target
$211.29 (+13.9% Upside)
Volume
4.07 million shares
Average Volume
6.21 million shares
Today's Range
$183.19
$186.14
50-Day Range
$170.01
$198.62
52-Week Range
$163.52
$218.66
Dividend Yield
3.57%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$305.59 +4.91 (+1.63%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$305.36 -0.23 (-0.07%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The recent price target increase to $418.00 by JPMorgan Chase & Co. indicates strong analyst confidence in the stock's potential for growth.
  • UnitedHealth Group has a consensus rating of "Moderate Buy," suggesting that a majority of analysts believe the stock is a good investment opportunity.
  • The current stock price is around $302, which may present a buying opportunity given the potential upside indicated by analysts.

Cons of UnitedHealth Group

  • Recent price targets from other analysts have been lowered significantly, with some dropping to as low as $350.00, indicating mixed sentiment in the market.
  • The stock has experienced volatility, with a 12-month high of $630.73 and a low of $248.88, which may concern risk-averse investors.
  • UnitedHealth Group's current ratio of 0.85 suggests that the company may have liquidity issues, as it indicates that current liabilities exceed current assets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$272.76 billion
P/E Ratio
12.80
Consensus Rating
Moderate Buy
Consensus Price Target
$427.09 (+39.8% Upside)
Volume
8.76 million shares
Average Volume
7.35 million shares
Today's Range
$299.33
$305.82
50-Day Range
$273.96
$585.30
52-Week Range
$248.88
$630.73
Dividend Yield
2.94%
Novartis stock logo

5. Novartis NYSE:NVS

$118.91 +1.39 (+1.18%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$118.91 0.00 (0.00%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • The stock is currently trading around $117.56, showing a stable price point within its 12-month range of $96.06 to $120.92, indicating potential for growth.
  • Recent upgrades from analysts, including a "strong-buy" rating from BNP Paribas, suggest positive market sentiment and potential for price appreciation.
  • Institutional ownership is significant, with 13.12% of shares held by institutional investors and hedge funds, indicating confidence from large financial entities.

Cons of Novartis

  • Despite recent upgrades, there are still three analysts who have rated the stock as a sell, indicating some skepticism about its future performance.
  • The stock has a price-to-earnings (P/E) ratio of 18.37, which may be considered high compared to industry averages, suggesting it could be overvalued.
  • Recent trading volumes have been lower than average, which may indicate reduced investor interest or liquidity issues.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$248.25 billion
P/E Ratio
18.58
Consensus Rating
Hold
Consensus Price Target
$123.38 (+3.8% Upside)
Volume
1.04 million shares
Average Volume
1.58 million shares
Today's Range
$117.50
$119.29
50-Day Range
$105.18
$120.69
52-Week Range
$96.06
$120.92
Dividend Yield
2.21%
Abbott Laboratories stock logo

6. Abbott Laboratories NYSE:ABT

$138.13 +4.87 (+3.65%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$137.99 -0.14 (-0.10%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • Abbott Laboratories has received multiple upgrades from analysts, with target prices reaching as high as $159.00, indicating strong confidence in the company's future performance.
  • The current stock price is around $132.75, which may present a buying opportunity for investors looking for growth potential.
  • The company reported a solid quarterly earnings performance, exceeding analysts' expectations with earnings per share of $1.09, showcasing its profitability and operational efficiency.

Cons of Abbott Laboratories

  • Despite positive earnings, Abbott Laboratories' revenue for the latest quarter was slightly below analyst estimates, which could raise concerns about future growth.
  • The stock has experienced fluctuations, with a 12-month high of $141.23 and a low of $99.71, indicating potential volatility that may deter risk-averse investors.
  • The company's price-to-earnings (P/E) ratio is around 17.22, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$231.85 billion
P/E Ratio
17.92
Consensus Rating
Moderate Buy
Consensus Price Target
$142.61 (+3.2% Upside)
Volume
9.89 million shares
Average Volume
6.09 million shares
Today's Range
$132.38
$139.06
50-Day Range
$128.45
$138.13
52-Week Range
$99.71
$141.23
Dividend Yield
1.77%
AstraZeneca stock logo

7. AstraZeneca NASDAQ:AZN

$70.54 -0.10 (-0.14%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$70.70 +0.16 (+0.23%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $70, reflecting a stable performance in the market.
  • AstraZeneca has shown strong earnings growth, with recent reports indicating earnings per share exceeding expectations, which can signal a healthy financial outlook.
  • Institutional investors hold a significant portion of AstraZeneca's stock, indicating confidence in the company's future performance.

Cons of AstraZeneca

  • The stock has experienced fluctuations, with a one-year high of $87.68 and a low of $61.24, indicating potential volatility.
  • Recent revenue reports have shown that actual earnings fell short of analyst expectations, which could raise concerns about future performance.
  • The company has a relatively high price-to-earnings ratio, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$219.08 billion
P/E Ratio
28.33
Consensus Rating
Moderate Buy
Consensus Price Target
$85.00 (+20.5% Upside)
Volume
3.65 million shares
Average Volume
5.19 million shares
Today's Range
$70.00
$70.91
50-Day Range
$66.23
$75.00
52-Week Range
$61.24
$87.68
Dividend Yield
2.92%
Merck & Co., Inc. stock logo

8. Merck & Co., Inc. NYSE:MRK

$80.38 +0.22 (+0.27%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$80.28 -0.09 (-0.12%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • The current stock price is around $78, which is significantly lower than its 52-week high, indicating potential for price appreciation.
  • Merck has a strong return on equity of over 43%, suggesting effective management and profitability, which can lead to higher shareholder returns.
  • The company recently reported earnings that exceeded analyst expectations, showcasing its ability to generate profits even in challenging market conditions.

Cons of Merck & Co., Inc.

  • Merck's revenue has shown a slight decline of 1.6% compared to the same quarter last year, which could indicate potential challenges in maintaining growth.
  • The stock has a beta of 0.38, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • Recent analyst ratings have been mixed, with some firms downgrading their outlook, indicating uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$201.28 billion
P/E Ratio
11.70
Consensus Rating
Hold
Consensus Price Target
$109.19 (+35.8% Upside)
Volume
15.90 million shares
Average Volume
13.04 million shares
Today's Range
$79.09
$81.46
50-Day Range
$73.46
$85.23
52-Week Range
$73.31
$134.63
Dividend Yield
4.04%
Intuitive Surgical stock logo

9. Intuitive Surgical NASDAQ:ISRG

$523.08 +7.99 (+1.55%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$522.50 -0.58 (-0.11%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $515, reflecting a recent increase in trading activity, which may indicate positive market sentiment.
  • Intuitive Surgical, Inc. reported earnings per share (EPS) of $1.81, surpassing analysts' expectations, which suggests strong financial performance and potential for growth.
  • The company achieved a revenue of $2.25 billion, exceeding consensus estimates, indicating robust demand for its products and services.

Cons of Intuitive Surgical

  • The stock has a high price-to-earnings (PE) ratio of 75.53, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been notable, with executives selling thousands of shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • The stock's beta of 1.67 indicates higher volatility compared to the market, meaning it may experience larger price swings, which can be risky for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$184.62 billion
P/E Ratio
76.70
Consensus Rating
Moderate Buy
Consensus Price Target
$588.95 (+12.6% Upside)
Volume
1.59 million shares
Average Volume
1.67 million shares
Today's Range
$510.78
$523.97
50-Day Range
$468.32
$565.94
52-Week Range
$413.82
$616.00
Dividend Yield
N/A
Boston Scientific stock logo

10. Boston Scientific NYSE:BSX

$104.12 +1.76 (+1.72%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$103.25 -0.87 (-0.84%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $102.38, reflecting a stable performance in the market.
  • Boston Scientific Co. reported a significant year-over-year revenue increase of over 20%, indicating strong growth potential.
  • The company has a solid return on equity of 18.67%, suggesting effective management and profitability.

Cons of Boston Scientific

  • The price-to-earnings ratio is relatively high at around 74.73, which may indicate that the stock is overvalued compared to its earnings.
  • Insider selling has been notable, with executives selling a total of 411,970 shares recently, which could signal a lack of confidence in the company's future performance.
  • The current ratio of 1.45, while above 1, suggests that the company has enough assets to cover its liabilities, but it may not be as strong as some competitors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.44 billion
P/E Ratio
76.00
Consensus Rating
Buy
Consensus Price Target
$116.09 (+11.5% Upside)
Volume
7.16 million shares
Average Volume
6.56 million shares
Today's Range
$102.05
$104.30
50-Day Range
$93.63
$106.61
52-Week Range
$71.88
$107.17
Dividend Yield
N/A
Thermo Fisher Scientific stock logo

11. Thermo Fisher Scientific NYSE:TMO

$404.34 +4.13 (+1.03%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$405.50 +1.16 (+0.29%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $400, which may present a buying opportunity for investors looking for value in the market.
  • Thermo Fisher Scientific Inc. reported a revenue of $10.36 billion for the latest quarter, exceeding analysts' expectations, indicating strong operational performance.
  • The company has a solid net margin of 15.19%, reflecting effective cost management and profitability, which can be attractive for investors seeking stable returns.

Cons of Thermo Fisher Scientific

  • Recent price target reductions by several analysts, including a drop to $475, may indicate concerns about future growth prospects.
  • The stock has experienced a significant decline from its 52-week high of $627.88, which could signal volatility and risk for potential investors.
  • With a price-to-earnings (P/E) ratio of 23.48, the stock may be considered overvalued compared to industry peers, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$151.08 billion
P/E Ratio
23.72
Consensus Rating
Moderate Buy
Consensus Price Target
$604.05 (+49.4% Upside)
Volume
2.08 million shares
Average Volume
1.94 million shares
Today's Range
$399.18
$406.16
50-Day Range
$390.17
$436.90
52-Week Range
$385.46
$627.88
Dividend Yield
0.43%
Amgen stock logo

12. Amgen NASDAQ:AMGN

$277.49 +5.05 (+1.85%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$277.67 +0.18 (+0.07%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $277.55, which may present a buying opportunity for investors looking for value in the biotech sector.
  • Amgen Inc. reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $4.90, indicating robust financial health and operational efficiency.
  • The company has shown a significant year-over-year revenue growth of 9.4%, suggesting a positive trend in its business performance and market demand for its products.

Cons of Amgen

  • The company has a high debt-to-equity ratio of 8.70, which may raise concerns about its financial leverage and ability to manage debt obligations effectively.
  • Despite recent earnings growth, the stock has experienced volatility, with a 52-week high of $346.85 and a low of $253.30, indicating potential risks for investors.
  • Amgen Inc. has a consensus rating of "Hold," suggesting that analysts are cautious about its short-term performance and may not see significant upside potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$146.49 billion
P/E Ratio
25.32
Consensus Rating
Hold
Consensus Price Target
$309.22 (+11.4% Upside)
Volume
3.69 million shares
Average Volume
2.82 million shares
Today's Range
$269.01
$280.01
50-Day Range
$262.28
$297.29
52-Week Range
$253.30
$346.85
Dividend Yield
3.49%
Stryker stock logo

13. Stryker NYSE:SYK

$386.80 +7.64 (+2.02%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$386.58 -0.22 (-0.06%)
As of 06/24/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • Stryker Co. reported earnings per share of $2.84 for the latest quarter, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company has shown a significant year-over-year revenue increase of approximately 11.9%, suggesting robust demand for its medical technology products.
  • With a return on equity of 23.74%, Stryker Co. demonstrates effective management and profitability, which can be attractive to investors looking for efficient use of equity.

Cons of Stryker

  • Despite recent growth, the stock has faced fluctuations, and some analysts have adjusted their price targets downward, indicating potential volatility.
  • Insider selling activity, such as the recent sale of 200,000 shares by a director, may raise concerns about the company's future prospects and insider confidence.
  • The dividend yield of 0.87% is relatively low compared to other investment opportunities, which may not attract income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$144.72 billion
P/E Ratio
52.27
Consensus Rating
Moderate Buy
Consensus Price Target
$427.30 (+10.5% Upside)
Volume
1.75 million shares
Average Volume
1.34 million shares
Today's Range
$377.64
$388.12
50-Day Range
$339.96
$394.63
52-Week Range
$314.93
$406.19
Dividend Yield
0.89%
Danaher stock logo

14. Danaher NYSE:DHR

$197.51 +1.17 (+0.60%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$197.84 +0.33 (+0.16%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $196, which reflects a strong market position and potential for growth.
  • Danaher Co. reported earnings per share (EPS) of $1.88, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $141 billion, suggesting stability and investor confidence.

Cons of Danaher

  • The stock has experienced a significant decrease in ownership by corporate insiders, which may signal concerns about future performance.
  • Danaher Co. has a relatively high price-to-earnings (P/E) ratio of 38.25, suggesting that the stock may be overvalued compared to its earnings.
  • The trading volume is lower than its average, which could indicate reduced investor interest or liquidity issues.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$140.51 billion
P/E Ratio
38.35
Consensus Rating
Moderate Buy
Consensus Price Target
$248.61 (+25.9% Upside)
Volume
2.74 million shares
Average Volume
3.46 million shares
Today's Range
$195.95
$198.73
50-Day Range
$184.79
$204.85
52-Week Range
$171.00
$281.70
Dividend Yield
0.65%
Pfizer stock logo

15. Pfizer NYSE:PFE

$24.30 +0.28 (+1.14%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$24.35 +0.05 (+0.19%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $24.31, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Pfizer Inc. has received multiple upgrades from analysts, including a "strong-buy" rating, suggesting confidence in its future performance.
  • Institutional investors hold a significant portion of Pfizer Inc.'s stock, with over 68% owned by hedge funds and other institutions, indicating strong institutional support.

Cons of Pfizer

  • Despite recent upgrades, some analysts maintain a "neutral" rating, indicating uncertainty about the stock's potential for significant growth.
  • The company's price-to-earnings (P/E) ratio is around 17.6, which may suggest that the stock is fairly valued, limiting upside potential.
  • There is a mixed sentiment among analysts, with one rating the stock as a sell, which could indicate potential risks for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$136.62 billion
P/E Ratio
17.61
Consensus Rating
Moderate Buy
Consensus Price Target
$29.17 (+20.0% Upside)
Volume
34.39 million shares
Average Volume
41.13 million shares
Today's Range
$24.11
$24.40
50-Day Range
$22.01
$24.85
52-Week Range
$20.92
$31.54
Dividend Yield
7.18%
Gilead Sciences stock logo

16. Gilead Sciences NASDAQ:GILD

$107.20 +1.01 (+0.95%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$107.28 +0.08 (+0.08%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The current stock price is around $110.55, which reflects a consensus rating of "Moderate Buy" from analysts, indicating positive market sentiment.
  • Gilead Sciences, Inc. has a strong dividend payout ratio of 66.53%, suggesting a commitment to returning value to shareholders through dividends.
  • Recent analyst upgrades have seen price targets raised, with firms like Morgan Stanley and Wells Fargo setting targets as high as $140.00, indicating potential for stock appreciation.

Cons of Gilead Sciences

  • Insider sales have totaled 48,500 shares in the last 90 days, which could signal a lack of confidence among some insiders regarding the stock's future performance.
  • Despite recent upgrades, some analysts have reduced their price targets, indicating mixed sentiments about the stock's short-term potential.
  • The company currently has only 0.27% of its stock owned by insiders, which may suggest limited insider confidence in the company's future growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$132.09 billion
P/E Ratio
22.57
Consensus Rating
Moderate Buy
Consensus Price Target
$110.55 (+3.1% Upside)
Volume
7.92 million shares
Average Volume
7.62 million shares
Today's Range
$106.00
$107.60
50-Day Range
$96.86
$113.00
52-Week Range
$66.01
$119.96
Dividend Yield
2.98%
Sanofi stock logo

17. Sanofi NASDAQ:SNY

$48.42 +0.24 (+0.50%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$48.53 +0.11 (+0.22%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi's stock is currently trading around $49.41, showing resilience in a fluctuating market, which may indicate a stable investment opportunity.
  • Recent analyst ratings have been favorable, with multiple firms issuing "buy" and "strong buy" ratings, suggesting confidence in the company's growth potential.
  • The company has a solid market capitalization of approximately $121 billion, indicating a strong position in the pharmaceutical industry.

Cons of Sanofi

  • The stock has experienced fluctuations, with a 12-month low of $45.80, indicating potential volatility that could concern risk-averse investors.
  • Despite positive ratings, some analysts have issued "neutral" ratings, suggesting that there may be limitations on the stock's upside potential in the near term.
  • Sanofi's price-to-earnings ratio is around 19.84, which may be considered high compared to industry averages, potentially indicating that the stock is overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$118.16 billion
P/E Ratio
17.29
Consensus Rating
Buy
Consensus Price Target
$61.50 (+27.0% Upside)
Volume
2.43 million shares
Average Volume
2.35 million shares
Today's Range
$48.39
$48.93
50-Day Range
$47.62
$55.44
52-Week Range
$45.80
$60.12
Dividend Yield
3.32%
Vertex Pharmaceuticals stock logo

18. Vertex Pharmaceuticals NASDAQ:VRTX

$450.27 +6.73 (+1.52%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$448.10 -2.16 (-0.48%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The stock has shown strong institutional support, with over 90% of shares owned by institutional investors and hedge funds, indicating confidence in the company's future performance.
  • Vertex Pharmaceuticals Incorporated has a solid market capitalization of approximately $113 billion, which reflects its significant presence and stability in the biotechnology sector.
  • Recent analyst ratings have been favorable, with multiple firms reaffirming "buy" ratings and raising price targets, suggesting potential for stock appreciation.

Cons of Vertex Pharmaceuticals

  • The company reported a negative net margin of 8.91%, which indicates that it is currently spending more than it earns, raising concerns about profitability.
  • Vertex Pharmaceuticals Incorporated has a price-to-earnings ratio of around -112, suggesting that it is not currently generating positive earnings, which can be a red flag for potential investors.
  • Despite revenue growth, the company missed earnings expectations in its latest report, which may lead to decreased investor confidence and stock volatility.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$113.90 billion
P/E Ratio
-114.86
Consensus Rating
Moderate Buy
Consensus Price Target
$513.14 (+14.0% Upside)
Volume
1.07 million shares
Average Volume
1.41 million shares
Today's Range
$441.00
$451.88
50-Day Range
$421.16
$509.50
52-Week Range
$377.85
$519.88
Dividend Yield
N/A
Medtronic stock logo

19. Medtronic NYSE:MDT

$86.12 +0.16 (+0.18%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$86.63 +0.51 (+0.59%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $86, which may present a buying opportunity for investors looking for value in the medical technology sector.
  • Medtronic plc recently reported strong quarterly earnings, exceeding analysts' expectations with a revenue of approximately $8.93 billion, indicating robust business performance.
  • The company has a history of increasing dividends, with a recent boost to $0.71 per share, reflecting a commitment to returning value to shareholders.

Cons of Medtronic

  • The stock has experienced fluctuations, with a 52-week high of $96.25 and a low of $75.96, indicating potential volatility that could concern risk-averse investors.
  • Despite recent earnings growth, the company's price-to-earnings ratio is around 23.75, which may be considered high compared to industry peers, suggesting that the stock could be overvalued.
  • Medtronic plc has a relatively high dividend payout ratio of 77.35%, which may limit its ability to reinvest in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$110.25 billion
P/E Ratio
23.79
Consensus Rating
Moderate Buy
Consensus Price Target
$97.87 (+13.6% Upside)
Volume
11.14 million shares
Average Volume
6.90 million shares
Today's Range
$84.94
$86.39
50-Day Range
$80.70
$88.47
52-Week Range
$75.96
$96.25
Dividend Yield
3.26%
Bristol Myers Squibb stock logo

20. Bristol Myers Squibb NYSE:BMY

$47.04 +0.12 (+0.25%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$47.04 +0.00 (+0.01%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $47.58, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Bristol-Myers Squibb has a strong portfolio of products, including recent advancements in treatments for various cancers and autoimmune diseases, which could drive future revenue growth.
  • The company has a high return on equity of 87.62%, indicating effective management and profitability, which is attractive to investors seeking strong financial performance.

Cons of Bristol Myers Squibb

  • The firm's quarterly revenue has decreased by 5.6% year-over-year, which may indicate challenges in maintaining sales momentum.
  • Despite a solid product lineup, the company reported a loss of $4.40 EPS in the previous quarter, raising concerns about profitability in the short term.
  • Analysts have issued a range of price targets, with some downgrading their expectations, which could signal uncertainty about the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.49 billion
P/E Ratio
17.62
Consensus Rating
Hold
Consensus Price Target
$58.00 (+23.3% Upside)
Volume
14.54 million shares
Average Volume
12.92 million shares
Today's Range
$46.71
$47.40
50-Day Range
$44.06
$50.68
52-Week Range
$39.35
$63.33
Dividend Yield
5.29%
HCA Healthcare stock logo

21. HCA Healthcare NYSE:HCA

$379.06 +0.34 (+0.09%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$381.14 +2.08 (+0.55%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $377, reflecting a strong market position and potential for growth.
  • HCA Healthcare, Inc. reported a significant earnings per share (EPS) of $6.45, exceeding analysts' expectations, indicating robust financial performance.
  • The company has a market capitalization of approximately $90.76 billion, showcasing its size and stability in the healthcare sector.

Cons of HCA Healthcare

  • The company has a high debt-to-equity ratio of 69.07, which may indicate financial risk and reliance on borrowed funds.
  • Despite recent performance, the stock has experienced volatility, with a fifty-two week range between $289.98 and $417.14, suggesting potential instability.
  • Insider ownership is relatively low at 1.30%, which may raise concerns about alignment between management and shareholder interests.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$91.11 billion
P/E Ratio
16.85
Consensus Rating
Moderate Buy
Consensus Price Target
$394.33 (+4.0% Upside)
Volume
1.10 million shares
Average Volume
1.46 million shares
Today's Range
$373.03
$379.23
50-Day Range
$317.93
$387.49
52-Week Range
$289.98
$417.14
Dividend Yield
0.76%
McKesson stock logo

22. McKesson NYSE:MCK

$721.58 -0.25 (-0.03%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$721.02 -0.56 (-0.08%)
As of 06/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $729, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Analysts have a consensus rating of "Moderate Buy" for McKesson Co., suggesting that many believe the stock has potential for growth.
  • Recent earnings reports show that McKesson Co. exceeded analysts' expectations, indicating strong financial performance and operational efficiency.

Cons of McKesson

  • Insider selling has been notable, with significant shares sold by executives, which may raise concerns about their confidence in the company's future.
  • The company's net margin is relatively low, indicating that while revenue is growing, profitability may not be as strong as desired.
  • Recent downgrades from some analysts suggest that not all market experts are optimistic about the stock's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$90.31 billion
P/E Ratio
27.94
Consensus Rating
Moderate Buy
Consensus Price Target
$696.42 (-3.5% Downside)
Volume
530,921 shares
Average Volume
921,927 shares
Today's Range
$708.16
$722.75
50-Day Range
$682.20
$730.39
52-Week Range
$464.42
$733.10
Dividend Yield
0.39%
Cigna Group stock logo

23. Cigna Group NYSE:CI

$316.83 -0.14 (-0.04%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$316.98 +0.15 (+0.05%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The Cigna Group recently reported strong earnings, with an EPS of $6.74, surpassing estimates and indicating robust financial health.
  • The current stock price is around $317, which may present a buying opportunity for investors looking for value in the health services sector.
  • Analysts have a positive outlook, with a consensus price target of approximately $380.39, suggesting potential upside for investors.

Cons of Cigna Group

  • The current ratio is 0.72, indicating that the company may have liquidity issues, as it has less current assets than current liabilities.
  • There has been a significant decrease in holdings by some institutional investors, which could signal a lack of confidence in the stock's future performance.
  • The debt-to-equity ratio stands at 0.65, suggesting that the company is somewhat leveraged, which could pose risks in a rising interest rate environment.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.68 billion
P/E Ratio
17.54
Consensus Rating
Buy
Consensus Price Target
$380.39 (+20.1% Upside)
Volume
1.32 million shares
Average Volume
1.70 million shares
Today's Range
$313.23
$317.77
50-Day Range
$301.90
$340.21
52-Week Range
$262.03
$370.83
Dividend Yield
1.91%
CVS Health stock logo

24. CVS Health NYSE:CVS

$67.65 +0.84 (+1.26%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$67.33 -0.33 (-0.48%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $66, which is significantly lower than the consensus target price of $74.75, indicating potential for price appreciation.
  • CVS Health Co. recently reported strong earnings, with an EPS of $2.25, surpassing analysts' expectations, which reflects robust financial performance.
  • The company has shown a revenue increase of 7.0% compared to the same quarter last year, suggesting growth in its business operations.

Cons of CVS Health

  • The stock has a relatively low quick ratio of 0.63, indicating potential liquidity issues that could affect short-term financial health.
  • CVS Health Co. has a debt-to-equity ratio of 0.77, which, while manageable, suggests that the company is using a significant amount of debt to finance its operations.
  • The stock's beta of 0.56 indicates lower volatility compared to the market, which may limit potential high returns for aggressive investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$84.52 billion
P/E Ratio
16.15
Consensus Rating
Moderate Buy
Consensus Price Target
$75.07 (+11.0% Upside)
Volume
10.27 million shares
Average Volume
10.87 million shares
Today's Range
$66.54
$68.21
50-Day Range
$60.03
$69.42
52-Week Range
$43.56
$72.51
Dividend Yield
4.00%
Elevance Health stock logo

25. Elevance Health NYSE:ELV

$376.48 +4.06 (+1.09%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$376.42 -0.06 (-0.01%)
As of 06/24/2025 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$84.14 billion
P/E Ratio
14.69
Consensus Rating
Moderate Buy
Consensus Price Target
$498.87 (+32.5% Upside)
Volume
1.06 million shares
Average Volume
1.57 million shares
Today's Range
$370.43
$377.87
50-Day Range
$372.33
$435.12
52-Week Range
$357.45
$567.26
Dividend Yield
1.84%
GSK stock logo

26. GSK NYSE:GSK

$38.66 +0.40 (+1.03%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$38.62 -0.04 (-0.09%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $40.36, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc reported strong quarterly earnings, with earnings per share of $1.13, exceeding analysts' expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 2.1%, suggesting growth potential and resilience in its business operations.

Cons of GSK

  • The stock has experienced volatility, recently gapping down from a previous close of $41.66 to open at $40.68, which may raise concerns about market stability.
  • Analysts have mixed ratings on GSK plc, with a consensus rating of "Hold," suggesting uncertainty about its future performance.
  • The company has a debt-to-equity ratio of 1.12, indicating a relatively high level of debt compared to equity, which could pose risks in economic downturns.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$78.33 billion
P/E Ratio
19.93
Consensus Rating
Hold
Consensus Price Target
$37.38 (-3.3% Downside)
Volume
4.82 million shares
Average Volume
4.92 million shares
Today's Range
$38.40
$38.91
50-Day Range
$35.38
$42.50
52-Week Range
$31.72
$44.67
Dividend Yield
4.41%
Zoetis stock logo

27. Zoetis NYSE:ZTS

$157.76 +0.42 (+0.27%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$158.52 +0.77 (+0.49%)
As of 06/24/2025 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $157, reflecting a recent increase of 1.4%, which may indicate positive market sentiment towards the company.
  • Zoetis Inc. has shown strong financial performance, reporting earnings per share (EPS) of $1.48, surpassing analyst expectations, which suggests robust profitability.
  • The company has a high return on equity of 55.48%, indicating effective management and a strong ability to generate profits from shareholders' equity.

Cons of Zoetis

  • The stock has experienced volatility, recently gapping down from a previous close of $161.67 to open at $157.09, which may raise concerns about short-term price stability.
  • Analysts have mixed opinions, with some downgrading their price targets, indicating potential uncertainty about the company's future growth prospects.
  • The company has a debt-to-equity ratio of 1.12, which suggests that it has a moderate level of debt compared to its equity, potentially increasing financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$70.05 billion
P/E Ratio
28.32
Consensus Rating
Buy
Consensus Price Target
$212.13 (+34.5% Upside)
Volume
4.55 million shares
Average Volume
2.56 million shares
Today's Range
$154.26
$158.65
50-Day Range
$146.78
$170.40
52-Week Range
$139.70
$200.33
Dividend Yield
1.27%
Cencora stock logo

28. Cencora NYSE:COR

$294.16 +1.03 (+0.35%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$292.68 -1.49 (-0.51%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is approximately $269.51, which may present a buying opportunity for investors looking for growth in the pharmaceutical distribution sector.
  • Recent insider trading activity indicates confidence in the company, with executives making significant transactions, suggesting they believe in the company's future performance.
  • Cencora, Inc. has a solid market presence in sourcing and distributing pharmaceutical products, which is crucial in a growing healthcare market.

Cons of Cencora

  • Recent insider sales, including a 21.96% decrease in the position of an executive vice president, may raise concerns about the company's short-term outlook.
  • The stock has experienced fluctuations, and the recent average sale price of $269.51 reflects a decrease in value, which could indicate volatility.
  • With a significant portion of stock owned by insiders, any negative sentiment or poor performance could lead to a rapid decline in stock value.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.82 billion
P/E Ratio
34.13
Consensus Rating
Moderate Buy
Consensus Price Target
$306.91 (+4.3% Upside)
Volume
1.18 million shares
Average Volume
1.51 million shares
Today's Range
$287.43
$294.43
50-Day Range
$278.35
$304.04
52-Week Range
$218.65
$309.35
Dividend Yield
0.75%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$522.27 +10.35 (+2.02%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$518.96 -3.31 (-0.63%)
As of 06/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The current stock price is around $509, which may present a buying opportunity for investors looking for value.
  • Regeneron Pharmaceuticals, Inc. has received multiple upgrades from analysts, including a recent strong-buy rating, indicating positive sentiment in the market.
  • The company has a solid market capitalization of over $55 billion, suggesting stability and a strong position in the biopharmaceutical sector.

Cons of Regeneron Pharmaceuticals

  • The company recently reported earnings per share (EPS) of $8.22, which missed analysts' expectations, raising concerns about its short-term performance.
  • Regeneron Pharmaceuticals, Inc. experienced a year-over-year revenue decline of 3.7%, which may indicate challenges in maintaining growth.
  • Analysts have set a consensus price target of around $836.48, suggesting that the stock may have limited upside potential in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.27 billion
P/E Ratio
13.30
Consensus Rating
Moderate Buy
Consensus Price Target
$822.58 (+57.5% Upside)
Volume
970,549 shares
Average Volume
892,382 shares
Today's Range
$515.79
$527.45
50-Day Range
$483.07
$614.79
52-Week Range
$476.49
$1,211.20
Dividend Yield
0.69%
Becton, Dickinson and Company stock logo

30. Becton, Dickinson and Company NYSE:BDX

$171.63 +1.91 (+1.12%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$171.57 -0.06 (-0.03%)
As of 06/24/2025 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The company has demonstrated strong earnings performance, recently reporting earnings per share that exceeded analyst expectations, indicating robust financial health.
  • Becton, Dickinson and Company has a solid market capitalization of approximately $48.33 billion, reflecting its stability and presence in the medical supplies sector.
  • The current stock price is around $192, which may present a buying opportunity for investors looking for growth in the healthcare sector.

Cons of Becton, Dickinson and Company

  • Recent downgrades from several analysts, including a reduction in price targets, may indicate a lack of confidence in the stock's short-term performance.
  • The company's revenue for the latest quarter fell short of consensus estimates, which could raise concerns about its growth trajectory.
  • With a dividend payout ratio of 79.39%, there may be limited room for future dividend increases, which could affect income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.64 billion
P/E Ratio
32.75
Consensus Rating
Hold
Consensus Price Target
$219.22 (+27.7% Upside)
Volume
2.90 million shares
Average Volume
2.02 million shares
Today's Range
$169.20
$171.93
50-Day Range
$165.13
$206.89
52-Week Range
$163.33
$251.99
Dividend Yield
2.45%
Haleon stock logo

31. Haleon NYSE:HLN

$10.50 +0.01 (+0.05%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$10.50 +0.01 (+0.05%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $11.25, reflecting a positive outlook from analysts who have upgraded their ratings recently.
  • Haleon plc has a market capitalization of approximately $46.77 billion, indicating a strong position in the consumer healthcare market.
  • Five research analysts have rated the stock with a buy rating, suggesting confidence in the company's growth potential.

Cons of Haleon

  • Despite recent upgrades, there are still five analysts who have rated the stock with a hold rating, indicating some uncertainty about its future performance.
  • The price-to-earnings ratio of 26.65 suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • The price-to-earnings-growth ratio of 2.96 indicates that the stock's growth may not justify its current price, raising concerns about long-term sustainability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.17 billion
P/E Ratio
26.91
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+17.4% Upside)
Volume
14.93 million shares
Average Volume
9.14 million shares
Today's Range
$10.46
$10.61
50-Day Range
$10.14
$11.42
52-Week Range
$8.25
$11.42
Dividend Yield
2.38%
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$15.10 +0.38 (+2.55%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$15.68 +0.58 (+3.88%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.95, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Recent institutional investments, such as Toronto Dominion Bank acquiring over 510,600 shares, indicate strong confidence in the company's future performance.
  • Takeda Pharmaceutical Company Limited has shown significant revenue potential, with quarterly revenues reported at $7.34 billion, although slightly below analyst expectations.

Cons of Takeda Pharmaceutical

  • The company recently reported earnings per share (EPS) of $0.16, which missed the consensus estimate of $0.24, raising concerns about its profitability.
  • Despite a strong market capitalization of approximately $47.57 billion, the stock has experienced fluctuations, with a 1-year low of $12.57, indicating potential volatility.
  • The net margin of 4.53% suggests that the company may face challenges in converting revenue into profit, which could affect long-term growth prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$46.84 billion
P/E Ratio
68.62
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
2.28 million shares
Average Volume
1.95 million shares
Today's Range
$14.99
$15.14
50-Day Range
$13.69
$15.39
52-Week Range
$12.80
$15.68
Dividend Yield
1.82%
Veeva Systems stock logo

33. Veeva Systems NYSE:VEEV

$281.40 +1.10 (+0.39%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$281.56 +0.15 (+0.05%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The current stock price is around $226, which may present a buying opportunity for investors looking for growth in the life sciences software sector.
  • Veeva Systems Inc. has a strong presence in the cloud-based software market specifically tailored for the life sciences industry, which is experiencing significant growth due to increasing demand for digital solutions.
  • Insider ownership stands at approximately 10.30%, indicating that company executives have a vested interest in the success of Veeva Systems Inc., which can align their goals with those of shareholders.

Cons of Veeva Systems

  • Recent insider sales, including a significant transaction by a senior vice president, may raise concerns about the company's short-term outlook and could indicate a lack of confidence among executives.
  • The stock has seen fluctuations, with recent insider sales totaling over 6,000 shares, which could suggest that insiders anticipate potential challenges ahead.
  • With a decrease in ownership percentages among insiders, there may be questions about the long-term commitment of key executives to the company's growth.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.80 billion
P/E Ratio
59.62
Consensus Rating
Moderate Buy
Consensus Price Target
$269.80 (-4.1% Downside)
Volume
886,456 shares
Average Volume
1.15 million shares
Today's Range
$279.81
$282.87
50-Day Range
$210.09
$289.99
52-Week Range
$177.41
$291.69
Dividend Yield
N/A
Edwards Lifesciences stock logo

34. Edwards Lifesciences NYSE:EW

$75.86 +0.54 (+0.72%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$75.34 -0.52 (-0.69%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $74.80, which may present a buying opportunity for investors looking for value in the medical research sector.
  • Recent earnings reports indicate strong performance, with the company surpassing analysts' expectations for earnings per share and revenue, suggesting robust operational efficiency.
  • Edwards Lifesciences Co. has a solid market capitalization of approximately $43.88 billion, indicating a strong position in the industry and potential for growth.

Cons of Edwards Lifesciences

  • Recent downgrades from analysts, including a shift from a "buy" to a "hold" rating, may indicate concerns about future performance and market conditions.
  • Insider selling activity has been noted, with significant shares sold by executives, which could signal a lack of confidence in the company's short-term outlook.
  • The stock has experienced fluctuations, with a 52-week high of $95.25 and a low of $58.93, indicating volatility that may deter risk-averse investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.18 billion
P/E Ratio
10.84
Consensus Rating
Hold
Consensus Price Target
$80.20 (+5.7% Upside)
Volume
4.61 million shares
Average Volume
5.22 million shares
Today's Range
$74.12
$76.63
50-Day Range
$69.23
$78.09
52-Week Range
$58.93
$95.25
Dividend Yield
N/A
IDEXX Laboratories stock logo

35. IDEXX Laboratories NASDAQ:IDXX

$530.50 +5.85 (+1.12%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$530.60 +0.10 (+0.02%)
As of 06/24/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $519.85, reflecting strong market interest and potential for growth.
  • IDEXX Laboratories, Inc. has seen significant institutional investment, with hedge funds and other institutional investors owning approximately 87.84% of the company's stock, indicating confidence in its future performance.
  • Recent filings show that Factory Mutual Insurance Co. increased its stake by 42.5%, suggesting positive sentiment among major investors.

Cons of IDEXX Laboratories

  • The price-to-earnings ratio is relatively high at 48.05, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider transactions show that a director sold shares, which could signal a lack of confidence in the company's short-term performance.
  • The company has a beta of 1.55, suggesting higher volatility compared to the market, which could lead to greater risk for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.19 billion
P/E Ratio
49.03
Consensus Rating
Moderate Buy
Consensus Price Target
$546.00 (+2.9% Upside)
Volume
386,993 shares
Average Volume
645,723 shares
Today's Range
$520.36
$530.74
50-Day Range
$402.38
$530.50
52-Week Range
$356.14
$530.74
Dividend Yield
N/A
Alcon stock logo

36. Alcon NYSE:ALC

$87.33 +1.98 (+2.32%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$88.61 +1.28 (+1.47%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $91.50, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a solid upward trend in its stock value.
  • Institutional ownership is significant, suggesting that large investors have confidence in the company's future prospects.

Cons of Alcon

  • Despite recent performance, the average daily volume has decreased, which may indicate reduced trading interest.
  • The company has experienced fluctuations in shares shorted, which could suggest uncertainty among investors.
  • There is a relatively high number of shares shorted, which could lead to volatility if investors decide to cover their positions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.10 billion
P/E Ratio
38.81
Consensus Rating
Moderate Buy
Consensus Price Target
$106.13 (+21.5% Upside)
Volume
1.31 million shares
Average Volume
1.17 million shares
Today's Range
$85.44
$87.51
50-Day Range
$84.77
$98.39
52-Week Range
$80.48
$101.10
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

37. Alnylam Pharmaceuticals NASDAQ:ALNY

$325.00 +11.87 (+3.79%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$324.94 -0.06 (-0.02%)
As of 06/24/2025 07:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The stock has recently been trading around $308, showing a positive trend in its market performance.
  • Alnylam Pharmaceuticals, Inc. has received multiple "buy" ratings from various research firms, indicating strong confidence in its future growth potential.
  • The company reported a significant revenue increase of over 20% compared to the same quarter last year, showcasing its strong market position and product demand.

Cons of Alnylam Pharmaceuticals

  • The company has a negative price-to-earnings (P/E) ratio, indicating that it is currently not profitable, which can be a red flag for potential investors.
  • Despite recent revenue growth, the company reported a loss per share, which may concern investors about its ability to achieve profitability in the near term.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio, suggesting that it relies heavily on debt financing, which can increase financial risk.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$40.83 billion
P/E Ratio
-155.50
Consensus Rating
Moderate Buy
Consensus Price Target
$335.32 (+3.2% Upside)
Volume
1.00 million shares
Average Volume
895,229 shares
Today's Range
$309.96
$326.03
50-Day Range
$230.50
$325.00
52-Week Range
$205.87
$326.03
Dividend Yield
N/A
Cardinal Health stock logo

38. Cardinal Health NYSE:CAH

$164.26 +0.27 (+0.17%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$162.55 -1.71 (-1.04%)
As of 06/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The stock has recently been upgraded to a "strong-buy" rating, indicating strong confidence from analysts in its future performance.
  • Cardinal Health, Inc. has a current stock price around $165, reflecting a significant increase from its 1-year low of $93.17, showcasing strong recovery and growth potential.
  • The company reported earnings per share (EPS) of $2.35, exceeding analysts' expectations, which suggests strong operational performance and profitability.

Cons of Cardinal Health

  • The company has a negative return on equity of 68.84%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • Despite recent revenue growth, the company reported revenue of $54.88 billion, which fell short of analysts' expectations, indicating potential challenges in meeting market demands.
  • Cardinal Health, Inc. has a relatively low net margin of 0.70%, suggesting that it may face challenges in maintaining profitability amidst rising costs.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.14 billion
P/E Ratio
25.63
Consensus Rating
Moderate Buy
Consensus Price Target
$157.43 (-4.2% Downside)
Volume
4.19 million shares
Average Volume
2.24 million shares
Today's Range
$161.57
$165.00
50-Day Range
$131.32
$165.51
52-Week Range
$93.17
$166.32
Dividend Yield
1.23%
ResMed stock logo

39. ResMed NYSE:RMD

$256.06 +1.54 (+0.60%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$257.25 +1.19 (+0.46%)
As of 06/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $240, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • ResMed Inc. has demonstrated strong financial performance, with a recent quarterly revenue increase of nearly 8% year-over-year, indicating robust demand for its products.
  • The company has a solid net margin of over 26%, suggesting efficient operations and profitability, which can lead to higher returns for investors.

Cons of ResMed

  • Despite recent growth, the stock has seen price target reductions from several analysts, indicating potential concerns about future performance.
  • With a debt-to-equity ratio of 0.12, while low, it may suggest limited leverage for expansion compared to competitors who might be more aggressive in their growth strategies.
  • Market volatility in the healthcare sector could impact ResMed Inc.'s stock performance, especially if economic conditions worsen.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.32 billion
P/E Ratio
28.74
Consensus Rating
Moderate Buy
Consensus Price Target
$259.33 (+1.3% Upside)
Volume
993,727 shares
Average Volume
984,532 shares
Today's Range
$252.35
$256.82
50-Day Range
$211.04
$256.06
52-Week Range
$180.34
$263.05
Dividend Yield
0.83%
argenex stock logo

40. argenex NASDAQ:ARGX

$568.06 +27.30 (+5.05%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$568.10 +0.05 (+0.01%)
As of 06/24/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The stock has received multiple upgrades from analysts, indicating strong confidence in its future performance.
  • Recent institutional investments show a growing interest in argenx SE, with significant stakes acquired by firms like Point72 Europe London LLP.
  • The current stock price is around $576, reflecting a solid market position and potential for growth.

Cons of argenex

  • The stock has experienced fluctuations, with a recent trading volume indicating some volatility in the market.
  • Despite positive analyst ratings, the stock has a high price-to-earnings ratio, which may suggest it is overvalued compared to its earnings.
  • Recent reports indicate that some institutional investors, like Polar Asset Management Partners Inc., have reduced their holdings, which could signal caution.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.02 billion
P/E Ratio
35.04
Consensus Rating
Buy
Consensus Price Target
$729.93 (+28.5% Upside)
Volume
385,885 shares
Average Volume
323,895 shares
Today's Range
$548.96
$574.64
50-Day Range
$532.27
$656.65
52-Week Range
$428.76
$678.21
Dividend Yield
N/A
Agilent Technologies stock logo

41. Agilent Technologies NYSE:A

$117.71 +1.58 (+1.36%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$117.68 -0.03 (-0.02%)
As of 06/24/2025 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. reported strong earnings per share of $1.31 for the latest quarter, surpassing analysts' expectations, which indicates robust financial performance and potential for future growth.
  • The company has a solid net margin of 17.59%, suggesting effective cost management and profitability, which can be attractive to investors looking for stable returns.
  • Agilent Technologies, Inc. has declared a quarterly dividend of $0.248 per share, reflecting a commitment to returning value to shareholders. This translates to an annualized dividend yield of approximately 0.86%.

Cons of Agilent Technologies

  • Recent price target reductions by several analysts, including a drop from $160.00 to $155.00 by JPMorgan Chase & Co., may signal concerns about the company's future performance and market position.
  • The stock has seen insider selling, with a director recently offloading shares, which could indicate a lack of confidence in the stock's short-term prospects.
  • With a payout ratio of 24.44%, while the dividend is sustainable, it may limit the company's ability to reinvest in growth opportunities, which could affect long-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.99 billion
P/E Ratio
29.06
Consensus Rating
Moderate Buy
Consensus Price Target
$140.92 (+19.7% Upside)
Volume
1.95 million shares
Average Volume
1.89 million shares
Today's Range
$116.57
$118.00
50-Day Range
$100.29
$120.72
52-Week Range
$96.43
$153.84
Dividend Yield
0.85%
GE HealthCare Technologies stock logo

42. GE HealthCare Technologies NASDAQ:GEHC

$71.98 +0.82 (+1.15%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$72.75 +0.77 (+1.07%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The company recently reported strong quarterly earnings, with earnings per share (EPS) of $1.01, exceeding analysts' expectations, indicating robust financial performance.
  • GE HealthCare Technologies Inc. has initiated a stock repurchase plan, allowing it to buy back $1.00 billion in shares, which often signals that the company believes its stock is undervalued and can enhance shareholder value.
  • The current stock price is around $71.62, which is significantly lower than its one-year high of $94.80, potentially offering a buying opportunity for investors looking for value.

Cons of GE HealthCare Technologies

  • Recent price target reductions by analysts, including a drop from $94.00 to $82.00 by Goldman Sachs, may indicate concerns about future growth prospects.
  • The stock has experienced volatility, with a one-year low of $57.65, which could be a red flag for risk-averse investors.
  • The dividend yield is relatively low at 0.20%, which may not attract income-focused investors looking for higher returns from dividends.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.58 billion
P/E Ratio
15.15
Consensus Rating
Moderate Buy
Consensus Price Target
$88.27 (+22.6% Upside)
Volume
8.74 million shares
Average Volume
3.48 million shares
Today's Range
$71.41
$72.29
50-Day Range
$60.48
$74.11
52-Week Range
$57.65
$94.80
Dividend Yield
0.20%
DexCom stock logo

43. DexCom NASDAQ:DXCM

$87.57 +7.73 (+9.68%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$87.64 +0.07 (+0.08%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • DexCom, Inc. has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and a target price of around $98.50, indicating potential for price appreciation.
  • The company reported a year-over-year revenue increase of approximately 12.5%, showcasing strong growth in its business operations.
  • Recent earnings per share were reported at $0.32, which, while slightly below expectations, reflects consistent performance compared to the previous year.

Cons of DexCom

  • The stock has experienced fluctuations, with a recent decline of about 1.0%, which may indicate volatility in the market.
  • Despite revenue growth, the earnings per share slightly missed consensus estimates, which could raise concerns about future profitability.
  • Insider selling activity has been noted, with significant shares sold recently, which may signal a lack of confidence among some executives.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.31 billion
P/E Ratio
65.35
Consensus Rating
Moderate Buy
Consensus Price Target
$98.50 (+12.5% Upside)
Volume
10.20 million shares
Average Volume
4.37 million shares
Today's Range
$79.40
$88.32
50-Day Range
$66.11
$87.57
52-Week Range
$57.52
$117.19
Dividend Yield
N/A
Humana stock logo

44. Humana NYSE:HUM

$238.61 +3.95 (+1.68%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$240.24 +1.63 (+0.68%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $239.66, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Humana Inc. reported strong earnings, exceeding analysts' expectations with earnings per share of $11.58, indicating robust financial performance.
  • Institutional investors and hedge funds own a significant portion of the company, with over 92% of the stock held by these entities, suggesting confidence in the company's future.

Cons of Humana

  • The stock has experienced a decline of about 1.5% recently, which may indicate short-term volatility and investor uncertainty.
  • Analysts have mixed ratings, with a consensus rating of "Hold," suggesting that some investors may not see significant upside potential in the near term.
  • Bank of America recently lowered its price target for Humana Inc. from $320.00 to $260.00, indicating a more cautious outlook on the stock's performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$28.32 billion
P/E Ratio
16.87
Consensus Rating
Hold
Consensus Price Target
$280.76 (+17.7% Upside)
Volume
1.28 million shares
Average Volume
1.81 million shares
Today's Range
$233.28
$239.56
50-Day Range
$224.81
$285.48
52-Week Range
$212.45
$406.46
Dividend Yield
1.51%
BeOne Medicines stock logo

45. BeOne Medicines NASDAQ:ONC

$266.80 +9.29 (+3.61%)
As of 06/24/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$28.22 billion
P/E Ratio
-71.72
Consensus Rating
Buy
Consensus Price Target
$319.00 (+19.6% Upside)
Volume
449,879 shares
Average Volume
323,933 shares
Today's Range
$262.53
$267.83
50-Day Range
$219.95
$276.53
52-Week Range
$141.31
$287.88
Dividend Yield
N/A
IQVIA stock logo

46. IQVIA NYSE:IQV

$158.63 +3.46 (+2.23%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$160.39 +1.76 (+1.11%)
As of 06/24/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $154, which may present a buying opportunity for investors looking for value in the medical research sector.
  • IQVIA Holdings Inc. reported a strong quarterly earnings per share (EPS) of $2.70, exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a revenue increase of 2.5% compared to the same quarter last year, reflecting growth in its operations and market demand.

Cons of IQVIA

  • The stock has experienced volatility, with a 52-week high of $252.88 and a low of $134.65, indicating potential risks associated with price fluctuations.
  • IQVIA Holdings Inc. has a relatively high debt-to-equity ratio of 2.19, which may raise concerns about the company's financial leverage and risk exposure.
  • Despite recent revenue growth, the company's net margin is around 8.61%, which may suggest limited profitability compared to competitors in the industry.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.84 billion
P/E Ratio
21.61
Consensus Rating
Moderate Buy
Consensus Price Target
$226.32 (+42.7% Upside)
Volume
1.61 million shares
Average Volume
1.65 million shares
Today's Range
$155.61
$158.93
50-Day Range
$136.96
$159.70
52-Week Range
$134.65
$252.88
Dividend Yield
N/A
Centene stock logo

47. Centene NYSE:CNC

$54.02 +0.62 (+1.15%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$54.02 +0.01 (+0.02%)
As of 06/24/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • The current stock price is around $55, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Centene Co. recently reported strong quarterly earnings, exceeding analysts' expectations, which indicates robust financial health and operational efficiency.
  • Institutional ownership is high, with over 93% of the stock held by hedge funds and other institutional investors, suggesting confidence in the company's future performance.

Cons of Centene

  • Despite recent earnings beats, the stock has experienced volatility, with a 52-week high of $80.59 and a low of $54.01, indicating potential risks in price stability.
  • Recent analyst reports have downgraded price targets, which may reflect concerns about future growth prospects and market conditions.
  • The healthcare sector is subject to regulatory changes, which can impact Centene's operations and profitability, introducing uncertainty for investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.57 billion
P/E Ratio
8.05
Consensus Rating
Moderate Buy
Consensus Price Target
$77.71 (+43.9% Upside)
Volume
4.23 million shares
Average Volume
4.94 million shares
Today's Range
$53.25
$54.24
50-Day Range
$53.44
$62.82
52-Week Range
$52.93
$80.59
Dividend Yield
N/A
BioNTech stock logo

48. BioNTech NASDAQ:BNTX

$105.09 +2.08 (+2.02%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$105.33 +0.24 (+0.23%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. More about BioNTech

Pros of BioNTech

  • The current stock price is around $99, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • BioNTech SE reported earnings per share of $1.08 for the latest quarter, significantly exceeding analysts' expectations, indicating strong performance and potential for future profitability.
  • The company has a robust market capitalization of approximately $25.35 billion, suggesting a solid position in the market and potential for stability.

Cons of BioNTech

  • The company has reported a negative return on equity of 2.35%, which may raise concerns about its ability to generate profit from shareholders' investments.
  • BioNTech SE experienced a decline in revenue of 19.5% year-over-year, indicating potential challenges in maintaining sales growth.
  • The firm has a negative net margin of 15.16%, suggesting that it is currently spending more than it earns, which could be a red flag for profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.76 billion
P/E Ratio
-30.91
Consensus Rating
Moderate Buy
Consensus Price Target
$137.86 (+31.2% Upside)
Volume
391,099 shares
Average Volume
942,233 shares
Today's Range
$103.25
$105.46
50-Day Range
$92.08
$120.54
52-Week Range
$76.53
$131.49
Dividend Yield
N/A
Mettler-Toledo International stock logo

49. Mettler-Toledo International NYSE:MTD

$1,186.60 +22.99 (+1.98%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$1,186.36 -0.24 (-0.02%)
As of 06/24/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The company reported earnings per share of $8.19 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Mettler-Toledo International Inc. has a net margin of 22.29%, suggesting that it retains a significant portion of revenue as profit, which is a positive indicator for profitability.
  • The current stock price is around $1,159.93, reflecting a stable valuation in the market, which may attract investors looking for solid investment opportunities.

Cons of Mettler-Toledo International

  • The company experienced a revenue decline of 4.6% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • Mettler-Toledo International Inc. has a negative return on equity of 591.54%, indicating that the company is not generating profit from its equity, which could deter potential investors.
  • Recent insider selling, including a significant transaction by a director, may signal a lack of confidence in the company's future prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$24.18 billion
P/E Ratio
29.59
Consensus Rating
Hold
Consensus Price Target
$1,304.40 (+9.9% Upside)
Volume
129,637 shares
Average Volume
152,200 shares
Today's Range
$1,171.68
$1,191.82
50-Day Range
$971.31
$1,218.94
52-Week Range
$946.69
$1,546.93
Dividend Yield
N/A
STERIS stock logo

50. STERIS NYSE:STE

$239.72 +2.81 (+1.19%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$239.56 -0.17 (-0.07%)
As of 06/24/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. More about STERIS

Pros of STERIS

  • The current stock price is around $250, which reflects a strong market position and potential for growth.
  • Recent upgrades from analysts, including a "strong-buy" rating, indicate positive sentiment and confidence in the company's future performance.
  • STERIS plc operates in the infection prevention sector, which is increasingly important in healthcare, suggesting a stable demand for its products and services.

Cons of STERIS

  • Recent insider sales, including significant transactions by the CEO and senior vice president, may raise concerns about the company's short-term outlook.
  • The stock has experienced a decrease in positions held by key executives, which could signal a lack of confidence in the company's immediate performance.
  • Despite positive ratings, the stock has a consensus price target that suggests limited upside potential compared to its current price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$23.31 billion
P/E Ratio
38.67
Consensus Rating
Moderate Buy
Consensus Price Target
$263.83 (+10.1% Upside)
Volume
467,766 shares
Average Volume
546,349 shares
Today's Range
$234.51
$240.06
50-Day Range
$219.08
$252.31
52-Week Range
$200.98
$252.79
Dividend Yield
0.97%